#China #Shanghai #IASO Bio #Cell Therapy #R&D Center

IASO Bio Celebrates Milestones in Cell Therapy Innovations

On May 20, 2025, IASO Biotherapeutics, commonly known as IASO Bio, commemorated two major achievements. The company officially unveiled its Global Research and Development (R&D) Center located in Shanghai's Waigaoqiao Free Trade Zone (FTZ). This event was complemented by the successful execution of their forum titled, "Opportunities and Challenges of China's Cell Therapy Globalization."

The inauguration drew more than 100 key stakeholders, including Xu Lai, the Deputy District Mayor of Shanghai's Pudong New Area, alongside international experts from diverse countries such as the UK, Russia, Mexico, Japan, and Indonesia. These attendees engaged in fruitful dialogues revolving around breakthrough technologies in cell therapy and deliberate strategies necessary for elevating China's cell therapy sector on the global stage.

The strategic significance of the FTZ cannot be overstated, as it is recognized as one of China's prime pilot regions authorized for R&D and manufacturing involving foreign investments in stem cell and gene therapies. Spanning an impressive 32,000 square meters, IASO Bio's new Global R&D Center is poised to leverage the FTZ's favorable policies—including tariff reductions, expedited customs procedures, and support for clinical trials. This facility aims to spearhead the advancement of next-generation cell and gene therapies, aligning its operations with IASO Bio's headquarters in Nanjing to further enhance the company’s international footprint.

Jinhua Zhang, the Founder and Chairwoman of IASO Bio, expressed heartfelt gratitude toward the Pudong New Area government, the Waigaoqiao Administration Bureau, and the Waigaoqiao Group for their unwavering support, highlighting their impact on the center’s innovation endeavors. "With Waigaoqiao as our strategic launchpad, we are well-positioned to lead the global charge in the cell therapy arena," she stated. Zhang reaffirmed the company’s dedication to breaking scientific boundaries in order to deliver transformative therapies to patients around the globe.

The ceremonial highlight involved attendees jointly activating a symbolic button representing innovation and hope, effectively marking the dawn of IASO Bio's new global chapter.

In conjunction with the opening festivities, IASO Bio took the opportunity to announce strategic alliances with various entities from Japan, Mexico, Russia, and Indonesia, as well as China’s Shenzhen Canyou Group. These collaborations target two essential goals: accelerating the international commercialization of CAR-T therapies and facilitating the introduction of innovative stem cell treatments for extensive patient populations globally.

Part of the event involved a panel discussion centered on two themes: 1) Global Synergy – Extending Access to Patients Worldwide and 2) Global Innovation - The Next Generation of Cell and Gene Therapy. Esteemed experts from Europe, Asia, and the Americas contributed their insights, presenting region-specific data to help navigate the trajectory of China's cell therapy landscape.

About IASO Bio

IASO Bio specializes in pioneering biopharmaceutical innovations, primarily focusing on the development of cutting-edge cell therapies and biologics aimed at treating oncological and autoimmune conditions. The company boasts an expansive array of capabilities that encompass everything from initial discovery phases to clinical trials, regulatory approvals, and eventual product commercialization. Its diverse pipeline includes more than ten novel treatments, highlighted by Equecabtagene Autoleucel—a fully human BCMA CAR-T injection approved by China's National Medical Products Administration in June 2023 and by the U.S. FDA for IND in December 2022. Drawing from its robust management team as well as a high-quality manufacturing and clinical development framework, IASO Bio endeavors to provide individuals both in China and globally with transformative, curable, and accessible therapies that fulfill various unmet medical needs.

For further insights, please visit IASO Bio’s website or LinkedIn.